Ananya Das, et al. https://doi.org/10.1016/j.clim.2021.108804.
Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 28/07/2021
- Mutation accumulation results in new variants of SARS-CoV-2 causing severe pathogenicity.
- SARS-CoV-2 infection the apoptosis of lymphocytes via tissue resident CD169+ macrophages.
- In SARS-CoV-2 infection NK cells shows high level of negative immune check point marker.
- Epitope mapping and stem cell therapy are now also considered as a novel approach for drug development.
- Clinical trials of various repurposed drugs are ongoing for developing potent vaccines
In December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a novel variant of coronavirus has recently emerged from Wuhan in China and has created havoc impulses across the world for a larger number of fatalities. At the same time studies are going on to discover vaccine against it or repurposing of approved drugs is widely adopted are under trial to eradicate the SARS-CoV-2 causing COVID-19. Reports have also shown that there are asymptomatic carriers of COVID-19 disease who can transmit the disease to others too. But the first line defense of the viral attack is body’s strong and well-coordinated immune response producing excessive inflammatory innate reaction and impaired adaptive host immune defense may leading death upon the misfunctioning. Considerable works are going on to establish the relation between immune parameters and viral entry that might alter both the innate and adaptive immune system COVID patient by up riding a massive cytokines and chemokines secretion. This review mainly gives an account on how SARS-CoV-2 interact with our immune system and how does our immune system respond to it and along with that drugs which are being used or can be used in fighting the disease and curative therapies as treatment for it has also been addressed.